← Back to Screener
Penumbra, Inc. (PEN)
Price$331.47
Favorite Metrics
Price vs S&P 500 (26W)24.39%
Price vs S&P 500 (4W)-7.54%
Market Capitalization$13.07B
P/E Ratio (Annual)73.56x
All Metrics
P/CF (Annual)54.77x
Book Value / Share (Quarterly)$36.39
P/TBV (Annual)8.57x
Revenue Growth (3Y)18.33%
Cash Flow / Share (Quarterly)$4.46
Price vs S&P 500 (YTD)4.28%
Gross Margin (TTM)67.14%
Net Profit Margin (TTM)12.66%
EPS (TTM)$4.52
10-Day Avg Trading Volume0.47M
EPS Excl Extra (TTM)$4.52
Revenue Growth (5Y)20.16%
EPS (Annual)$4.52
ROI (Annual)12.25%
Gross Margin (Annual)67.14%
Net Profit Margin (5Y Avg)4.58%
Cash / Share (Quarterly)$13.89
P/E Basic Excl Extra (TTM)73.56x
Revenue Growth QoQ (YoY)22.14%
EPS Growth (5Y)-23.21%
P/E Normalized (Annual)73.56x
ROA (Last FY)9.73%
Revenue Growth TTM (YoY)17.50%
EBITD / Share (TTM)$4.85
ROE (5Y Avg)4.35%
Operating Margin (TTM)13.48%
Cash Flow / Share (Annual)$4.46
P/B Ratio9.16x
P/B Ratio (Quarterly)8.53x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)9.20x
ROA (TTM)10.39%
EPS Growth QoQ (YoY)46.03%
EV / EBITDA (TTM)67.72x
EPS Incl Extra (Annual)$4.52
Current Ratio (Annual)6.64x
Quick Ratio (Quarterly)4.01x
3-Month Avg Trading Volume0.86M
52-Week Price Return23.00%
EV / Free Cash Flow (Annual)73.78x
P/E Incl Extra (TTM)73.56x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$36.23
P/S Ratio (Annual)9.31x
Asset Turnover (Annual)0.77x
52-Week High$362.41
Operating Margin (5Y Avg)4.19%
EPS Excl Extra (Annual)$4.52
CapEx CAGR (5Y)20.81%
Tangible BV CAGR (5Y)17.64%
26-Week Price Return28.37%
Quick Ratio (Annual)4.01x
13-Week Price Return4.05%
Total Debt / Equity (Annual)0.02x
Current Ratio (Quarterly)6.64x
Enterprise Value$12,906.75
Revenue / Share Growth (5Y)17.94%
Asset Turnover (TTM)0.82x
Book Value / Share Growth (5Y)15.61%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)1.10x
Pretax Margin (Annual)14.61%
Cash / Share (Annual)$13.89
3-Month Return Std Dev29.83%
Gross Margin (5Y Avg)64.32%
Net Income / Employee (TTM)$0
EBITDA CAGR (5Y)-22.08%
ROE (Last FY)12.45%
EPS Basic Excl Extra (Annual)$4.52
P/FCF (TTM)74.72x
Receivables Turnover (TTM)7.85x
EV / Free Cash Flow (TTM)73.78x
Total Debt / Equity (Quarterly)0.02x
EPS Incl Extra (TTM)$4.52
Receivables Turnover (Annual)7.85x
ROI (TTM)13.19%
P/S Ratio (TTM)9.31x
Pretax Margin (5Y Avg)4.59%
Revenue / Share (Annual)$35.72
Tangible BV / Share (Annual)$36.23
Forward P/E66.55x
Free OCF CAGR (5Y)100.55%
Price vs S&P 500 (52W)-6.83%
P/E Ratio (TTM)73.56x
EPS Growth TTM (YoY)1389.20%
Year-to-Date Return6.92%
5-Day Price Return0.88%
EPS Normalized (Annual)$4.52
ROA (5Y Avg)3.35%
Net Profit Margin (Annual)12.66%
Month-to-Date Return1.23%
Cash Flow / Share (TTM)$1.73
EBITD / Share (Annual)$4.85
EPS Growth (3Y)36.66%
Operating Margin (Annual)13.48%
LT Debt / Equity (Annual)0.00x
P/CF (TTM)54.77x
ROI (5Y Avg)4.27%
P/E Excl Extra (TTM)73.56x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$4.52
P/TBV (Quarterly)8.57x
P/B Ratio (Annual)8.53x
Inventory Turnover (TTM)1.10x
Pretax Margin (TTM)14.61%
Book Value / Share (Annual)$36.39
Price vs S&P 500 (13W)3.37%
Net Margin Growth (5Y)-33.30%
Beta0.77x
P/FCF (Annual)74.72x
Revenue / Share (TTM)$35.61
ROE (TTM)13.43%
52-Week Low$221.26
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.29
3.48
3.48
3.50
Industry Peers — Surgical & Medical Instruments(108)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
PENPenumbra, Inc. | 9.31x | 20.16% | 67.14% | 13.48% | $331.47 |
SYKStryker Corporation | 5.15x | 11.84% | 64.57% | 19.43% | $338.38 |
BSXBoston Scientific Corp. | 4.76x | 15.16% | 69.01% | 18.00% | $63.42 |
MMM3M Company | 3.18x | -4.97% | 39.92% | 18.55% | $150.55 |
MDLNMedline Inc. Class A common stock | 2.21x | — | 26.44% | 7.78% | $46.94 |
BDXBecton, Dickinson and Co. | 2.01x | 6.32% | 46.42% | 12.15% | $154.82 |
RMDResMed Inc. | 6.06x | 11.72% | 60.85% | 33.70% | $224.72 |
DXCMDexCom, Inc. | 5.23x | 19.33% | 62.09% | 19.56% | $61.23 |
WSTWest Pharmaceutical Services, Inc. | 6.22x | 7.44% | 35.91% | 19.03% | $269.81 |
PODDInsulet Corporation | 5.31x | 24.53% | 71.63% | 12.92% | $201.47 |
GMEDGLOBUS MEDICAL INC | 4.34x | 30.08% | 67.41% | 20.33% | $92.76 |
About
US-based Penumbra manufactures minimally invasive medical devices for mechanical removal of blood clots in acute care settings. The company's thrombectomy and embolization devices address stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular conditions, sold primarily to hospitals and physicians.